AML-M5
anemia
genetic test
·Administration： (1) Induction of remission therapy(2) Post-induction therapy monitoring: ·Bone marrow primitive cell residues ·Proliferation
prognosis
·reduced blood celll count
hematopoietic dysfunction
·FLT3-IDT（77.3%）·BCOR(100%）
·Elevated plasma D-dimer indicates secondary hyperfibrinolysis·Elevated PT as well as PT-INR indicate coagulation dysfunction·Decreased AT III suggests that the patient may be suffering from DIC
·higher PT、TT and D-Di·lower Fib
therapeutic regimen
The remaining blood is returned to the donor through the return end of the transfusion
·DEK::NUP214K、NUP214::DEK(+) and chromosome examination identify AML
support
·Post-treatment monitoring: closely monitoring after transplantation ·monitoring any complications that may arise·The entire transplant process may take days or weeks to complete
disease
chemotherapy treatment period
·tachycardia·hypertension·increased RDW·decreased HCT
bone marrow biopsy
guess
Result
chromosome examination
·splenic enlargement
·Inability to concentrate and fatigue·pale palpebral conjunctiva·lower erythrocyte and hemoglobin level
·continuous bleeding·bleeding gums·multiple ecchymoses and petechiae
bone marrow transplant
examination
Coagulation disorders
coagulation tests
